MC RCT - BPO vs Adapalene

Molluscum Contagiosum Clinical Trial

Official title:

Randomized Controlled Trial Comparing the Efficacy of Adapalene 0.1% Gel to 10% Benzoyl Peroxide in Treating Molluscum Contagiosum.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05536882
• Other study ID #: IRB# 14663
• Status: Withdrawn
• Phase: Phase 3
• Start date: May 18, 2022
• Est. completion date: October 9, 2023

Study information

• Verified date: March 2024
• Source: University of Oklahoma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Non-blinded randomized controlled trial comparing efficacy of topical benzoyl peroxide 10% (vehicle choice per patient preference: e.g. gel, cream, lotion, wash) to topical adapalene 0.1% gel in the treatment of molluscum contagiosum in children aged 1 year old to 14 years old.

• Two treatment wings: topical benzoyl peroxide 10% (vehicle choice per patient preference) applied 1-2x daily as tolerated vs adapalene 0.1% gel applied 1-2x daily as tolerated.

• Primary outcome: Complete clearance at 12wks (defined as lack of identifiable papular molluscum contagiosum lesions on physical exam)

• Secondary outcomes: % change in lesion count at 12wks.

Description:

• During the course of their normal workday, OU dermatology faculty and residents will be responsible for identifying and recruiting treatment-naïve patients being seen at the OU dermatology clinic for the diagnosis of molluscum contagiosum. These same faculty and residents will be responsible for approaching these patients regarding participation in the study. Chart review will not be a part of this selection process aside from what would naturally be done in the course of the patients' care. The same faculty and residents would be responsible for explaining the risks and benefits of study participation, obtaining written consent for study participation from a parent or guardian, obtaining verbal assent from patients aged 7-14 years old (as well as written assent for those capable of reading/writing), and randomizing patients to respective treatment wings using an online random number generator.

• # of MC lesions counted at time of recruitment, re-assessed at single follow up appointment at 12wks

• List of enrolled patients kept in excel spreadsheet on encrypted department shared drive. Data points added alongside patient names until all data points collected for an individual patient, then identifying information removed and replaced with a study number which will be used to refer to their de-identified data set going forward.

• Patients/caregivers would be responsible for obtainment and application of respective medications (both medications available over the counter for < $15)

• Primary and secondary outcomes will be assessed via Chi-square test

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 9, 2023
• Est. primary completion date: October 9, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 14 Years

Eligibility

Inclusion Criteria:

• Children aged 1 year to 14 years old seen in an OU Dermatology resident or faculty clinic and diagnosed with molluscum contagiosum who have not received prior treatment for this condition, and whose parent/guardian(s) desire treatment for this condition.

Exclusion Criteria:

• Patients who have received prior treatment for molluscum contagiosum.

• Patients with a history of adverse reaction to any topical retinoid, benzoyl peroxide, cinnamon, or other benzoic derivatives (e.g., salicylic acid, hydroquinone, catechol, vanillin).

• Pregnant females.

• Patients with caregivers who do not speak English.

• Patients with caregivers who are unable to provide consent.

• Patients who decline to assent for participation.

Related Conditions & MeSH terms

• Molluscum Contagiosum

Intervention

Drug:
• Benzoyl peroxide
See arm description
• Adapalene Gel
See arm description

Locations

Country	Name	City	State
United States	OU Health Department of Dermatology	Oklahoma City	Oklahoma

Sponsors (1)

Lead Sponsor	Collaborator
University of Oklahoma

Country where clinical trial is conducted

United States, 

References & Publications (7)

Gupta, M. Adapalene in management of molluscum contagiosum in pediatric population. Our Dermatology Online. 2019, Vol. 10, 4, pp. 391-392.

Kashif M, Tahir R, Hussain I. Efficacy and safety of trichloroacetic acid 35% versus adapalene 0.1% in treatment of molluscum contagiosum in children. Journal of Pakistan Association of Dermatologists. 2016, Vol. 26, 4, pp. 366-370.

Kim MS, Chun DK, Lee YS, et al. Treatment of Molluscum Contagiosum with Topical Tretinoin Therapy. Korean J Dermatol. 2001;39(6):666-670.

Na G, et al. P074 Clinical experience of adapalene on molluscum contagiosum. ?????(? ???). 2016;68(2):373-373.

Rajouria EA, Amatya A, Karn D. Comparative study of 5 % potassium hydroxide solution versus 0.05% tretinoin cream for Molluscum Contagiosum in children. Kathmandu Univ Med J (KUMJ). 2011 Oct-Dec;9(36):291-4. doi: 10.3126/kumj.v9i4.6347. — View Citation

Saryazdi, S. The Comparative Efficancy of Benzoyl Peroxide 10% Cream and Tretinoin 0.05% Cream In The Treatment of Molluscum Contagiosum. Pediatric Derm. 2004, Vol. 20, 3, p. 399.

Scheinfeld N. Treatment of molluscum contagiosum: a brief review and discussion of a case successfully treated with adapelene. Dermatol Online J. 2007 Jul 13;13(3):15. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence and severity of irritant contact dermatitis and other adverse events		12 weeks
Primary	Complete clearance at 12 weeks	Defined as lack of identifiable papular molluscum contagiosum lesions on physical exam at 12 week follow up visit	12 weeks
Secondary	% change in lesion count at 12 weeks		12 weeks